{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:53:02Z","timestamp":1761630782801},"reference-count":30,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.medcli.2017.02.012","type":"journal-article","created":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T05:35:14Z","timestamp":1490160914000},"page":"517-523","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tratamiento del mieloma m\u00faltiple asintom\u00e1tico: recomendaciones del Grupo Espa\u00f1ol de Mieloma"],"prefix":"10.1016","volume":"148","author":[{"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2017.02.012_bib0155","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.02.012_bib0160","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","author":"Kristinsson","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.02.012_bib0165","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2017.02.012_bib0170","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.02.012_bib0175","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1038\/leu.2014.230","article-title":"The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0180","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1056\/NEJMc1106428","article-title":"Diagnosis of smoldering multiple myeloma","volume":"365","author":"Rajkumar","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.02.012_bib0185","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0190","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/leu.2014.313","article-title":"Classifying ultra-high risk smoldering myeloma","volume":"29","author":"Waxman","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0195","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: A Danish population-based cohort study","volume":"97","author":"Sorrig","year":"2016","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.medcli.2017.02.012_bib0205","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.02.012_bib0210","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.02.012_bib0215","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"Perez-Persona","year":"2010","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.02.012_bib0220","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0225","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1182\/blood.V124.21.3363.3363","article-title":"Smoldering multiple myeloma: Impact of the evolving pattern on early progression","volume":"124","author":"Fern\u00e1ndez de Larrea","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.02.012_bib0230","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: Natural history and recognition of an en evoluci\u00f3n type","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.02.012_bib0235","article-title":"Evolving changes in M-protein (M), quantitative involved immunoglobulin (Ig), and hemoglobin (Hb) to identify patients (pts) with ultra high-risk smoldering multiple myeloma (UHR-SMM)","volume":"34","author":"Kumar Ravi","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.02.012_bib0240","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1038\/leu.2016.123","article-title":"Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma","volume":"30","author":"Gonzalez-Calle","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0245","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2014.75","article-title":"Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma","volume":"28","author":"Merz","year":"2014","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0250","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/leu.2015.291","article-title":"18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease","volume":"30","author":"Zamagni","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0255","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1038\/bcj.2015.87","article-title":"Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: Identification of patients needing therapy","volume":"5","author":"Siontis","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.medcli.2017.02.012_bib0260","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.medcli.2017.02.012_bib0265","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.02.012_bib0270","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3324\/haematol.2015.124651","article-title":"Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)","volume":"100","author":"Khan","year":"2015","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2017.02.012_bib0275","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.02.012_bib0280","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3379.3379","article-title":"Predictive significance of serum beta 2-microglobulin levels and M-protein velocity for symptomatic progression of smoldering multiple myeloma","volume":"124","author":"Muta","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.02.012_bib0285","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1182\/blood.V124.21.2071.2071","article-title":"Prediction of progression of smouldering into therapy requiring multiple myeloma by easily accessible clinical factors [in 527 patients]","volume":"124","author":"Hajek","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.02.012_bib0290","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.02.012_bib0295","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): Long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2017.02.012_bib0300","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317301537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317301537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T06:27:05Z","timestamp":1601792825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775317301537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0025775317301537"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2017.02.012","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento del mieloma m\u00faltiple asintom\u00e1tico: recomendaciones del Grupo Espa\u00f1ol de Mieloma","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2017.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}